Using Probiotics to Support Women's Health

The Promise of Strain-Specific Probiotics

New research is confirming that when it comes to probiotics, specificity matters. Rather than taking a broad spectrum approach, using specific strains studied for particular health conditions produces better outcomes. Just as different vitamins serve discrete functions in the body, probiotic strains have unique effects.

A 2018 meta-analysis demonstrated that a probiotic only provides benefits if you use the exact strain researched for that disease or condition. An example is in irritable bowel syndrome (IBS), where Lactobacillus plantarum MF1298 showed no benefits, but a different strain, L. plantarum 299V, improved IBS symptoms in multiple studies.

  

Two Potent Strains for Women’s Health

When it comes to women’s urogenital health, the most extensively studied combination contains Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. A 2021 review found this duo has the highest level of evidence as a probiotic for bacterial vaginosis and vulvovaginal candidiasis (VVC).

Multiple studies confirm taking just 2 billion CFU daily of GR-1 and RC-14 orally helps resolve bacterial vaginosis and VVC. The strains’ benefits include:

 
• Restoring Lactobacillus-dominant vaginal flora

 

• Preventing pathogen colonization

 

• Disrupting biofilms that infections hide behind

 
 

• Decreasing inflammatory cytokines

Comparing Oral and Vaginal Probiotic Delivery

While earlier research tested vaginal probiotic suppositories, more recent studies favor oral capsules. Oral delivery demonstrates:

 
• Good vaginal colonization by probiotic strains

 

• More convenience for patients

 

• Similar or greater effectiveness compared to vaginal administration

Therefore, the current recommendation is to take GR-1/RC-14 combinations orally instead of intravaginally. The only exception would be a personal preference for suppositories.

Probiotics Alone or With Antibiotics?

Studies have now proven GR-1 and RC-14 successfully treat bacterial vaginosis without any antibiotics:

 
• 61.5% taking probiotics had normal vaginal flora after 6 weeks, compared to just 27% on placebo

 
 

• Taking 2 billion CFU daily was effective

However, combining probiotics with antibiotics does further improve outcomes:

 
• 75% positive outcome at 4 weeks taking antibiotics + double dose probiotics

 

• Up to 88% resolution at 4 weeks with dual therapy

  

The strains’ natural antibiotic resistance allows taking them concurrently or 1-2 hours after antibiotics. Critically, adding probiotics prevents the antibiotic resistant infections that often recur after antibiotic therapy alone.

Treating Other Urogenital Conditions

There is less research on GR-1 and RC-14 for urinary tract infections (UTIs) and other urogenital problems. But a 12-month study did find:

 

 
• Similar UTI reduction taking probiotics versus antibiotics

 

• Far lower antibiotic resistant infections with probiotics

The strains’ ability to prevent pathogen invasion across mucosal barriers suggests applications beyond bacterial vaginosis and yeast. More studies are needed, but GR-1 and RC-14 show promise for stubborn conditions like recurrent UTIs and interstitial cystitis.

Safety and Tolerability

As lactic acid bacteria, GR-1 and RC-14 demonstrate an excellent safety profile. Studies note fewer adverse effects compared to antibiotic therapy. Small trials also support using this combination safely during pregnancy without harming mom or baby.

Duration of Treatment

Clinical trials show positive outcomes in as little as 1-2 weeks of probiotic therapy. However, they typically continue treatment for 4-6 weeks to resolve bacterial vaginosis, vulvovaginal candidiasis and other vaginal infections. For recurrent UTI sufferers, year-long studies demonstrate lasting benefits.

Overall duration depends on the severity of imbalance, how the individual responds, and the likelihood of re-exposure to pathogens. Some women require shorter courses, while others need ongoing probiotic support.

Mechanisms of Action

Research continues to uncover how GR-1 and RC-14 exert their protective effects. These include:

 
• Producing biosurfactants that disrupt biofilms and prevent pathogen adhesion

 

• Strengthening gut barrier function to reduce translocation of bacteria like Salmonella

 

• Stimulating anti-inflammatory immune activity

 

• Increasing gonadal hormone levels important for urogenital health

Identifying these mechanisms helps explain the strains’ clinical results and expand potential therapeutic applications.

  

Taxonomy Changes on the Horizon

Finally, those using GR-1 and RC-14 should be aware of coming taxonomy revisions. The Lactobacillus genus will likely split into 25 genera. But the all-important alphanumeric strain identifiers will remain to reduce confusion. So GR-1 and RC-14 will still refer to the same well-researched probiotic strains. This allows consumers and practitioners to reliably track their benefits for female urogenital and reproductive health.